Dorsomorphin 2HCl

Catalog No. A13720

Dorsomorphin, also known as BML-275, is a selective small molecule inhibitor of BMP signaling, which promotes cardiomyogenesis in embryonic stem cells. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling.
  • Kameshima S, .et al. Eukaryotic elongation factor 2 (eEF2) kinase/eEF2 plays protective roles against glucose deprivation-induced cell death in H9c2 cardiomyoblasts, Apoptosis, 2019, Feb 8 PMID: 30737648
Catalog Num A13720
M. Wt 472.41
Formula C24H27Cl2N5O
Purity >98%
Storage at -20 °C 3 years (powder form); at -20 °C 6 months (Solution base)
CAS No. 1219168-18-9
Synonyms Compound C, BML-275, BML275, BML 275
SMILES C1CCN(CC1)CCOC2=CC=C(C=C2)C3=CN4C(=C(C=N4)C5=CC=NC=C5)N=C3.Cl.Cl
Dorsomorphin, also known as BML-275, is a selective small molecule inhibitor of BMP signaling, which promotes cardiomyogenesis in embryonic stem cells. Dorsomorphin reverses the mesenchymal phenotype of breast cancer initiating cells by inhibition of bone morphogenetic protein signaling.
Targets
AMPK (Cell-free assay)
109 nM(Ki)
In vitro (25°C) DMSO Insoluble
Water 87 mg/mL (184.15 mM)
Ethanol Insoluble
In vivo PBS 14 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 21.17 mL 105.84 mL 211.68 mL
0.5 mM 4.23 mL 21.17 mL 42.34 mL
1 mM 2.12 mL 10.58 mL 21.17 mL
5 mM 0.42 mL 2.12 mL 4.23 mL

*The above data is based on the productmolecular weight 472.41. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.